T-Lymphocytes
"T-Lymphocytes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Descriptor ID |
D013601
|
MeSH Number(s) |
A11.118.637.555.567.569 A15.145.229.637.555.567.569 A15.382.490.555.567.569
|
Concept/Terms |
T-Lymphocytes- T-Lymphocytes
- T Lymphocytes
- T-Lymphocyte
- T-Cells
- T Cells
- T-Cell
- Thymus-Dependent Lymphocytes
- Lymphocyte, Thymus-Dependent
- Lymphocytes, Thymus-Dependent
- Thymus Dependent Lymphocytes
- Thymus-Dependent Lymphocyte
|
Below are MeSH descriptors whose meaning is more general than "T-Lymphocytes".
Below are MeSH descriptors whose meaning is more specific than "T-Lymphocytes".
This graph shows the total number of publications written about "T-Lymphocytes" by people in this website by year, and whether "T-Lymphocytes" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 16 | 3 | 19 | 1994 | 15 | 8 | 23 | 1995 | 6 | 10 | 16 | 1996 | 10 | 10 | 20 | 1997 | 20 | 5 | 25 | 1998 | 21 | 8 | 29 | 1999 | 18 | 6 | 24 | 2000 | 22 | 8 | 30 | 2001 | 17 | 6 | 23 | 2002 | 11 | 9 | 20 | 2003 | 20 | 12 | 32 | 2004 | 22 | 16 | 38 | 2005 | 26 | 9 | 35 | 2006 | 22 | 17 | 39 | 2007 | 17 | 10 | 27 | 2008 | 20 | 17 | 37 | 2009 | 23 | 13 | 36 | 2010 | 15 | 14 | 29 | 2011 | 12 | 21 | 33 | 2012 | 16 | 12 | 28 | 2013 | 27 | 20 | 47 | 2014 | 15 | 13 | 28 | 2015 | 17 | 12 | 29 | 2016 | 10 | 7 | 17 | 2017 | 17 | 10 | 27 | 2018 | 15 | 21 | 36 | 2019 | 20 | 20 | 40 | 2020 | 15 | 24 | 39 | 2021 | 20 | 19 | 39 | 2022 | 7 | 12 | 19 | 2023 | 0 | 8 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "T-Lymphocytes" by people in Profiles.
-
Stensland ZC, Magera CA, Broncucia H, Gomez BD, Rios-Guzman NM, Wells KL, Nicholas CA, Rihanek M, Hunter MJ, Toole KP, Gottlieb PA, Smith MJ. Identification of an anergic BND cell-derived activated B cell population (BND2) in young-onset type 1 diabetes patients. J Exp Med. 2023 Aug 07; 220(8).
-
Hay ZLZ, Knapp JR, Magallon RE, O'Connor BP, Slansky JE. Low TCR Binding Strength Results in Increased Progenitor-like CD8+ Tumor-Infiltrating Lymphocytes. Cancer Immunol Res. 2023 05 03; 11(5):570-582.
-
Hu X, Manner K, DeJesus R, White K, Gattis C, Ngo P, Bandoro C, Tham E, Chu EY, Young C, Wells F, Basco R, Friera A, Kangeyan D, Beauchesne P, Dowdle WE, Deuse T, Fry TJ, Foster AE, Schrepfer S. Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice. Nat Commun. 2023 04 10; 14(1):2020.
-
Ramos SA, Armitage LH, Morton JJ, Alzofon N, Handler D, Kelly G, Homann D, Jimeno A, Russ HA. Generation of functional thymic organoids from human pluripotent stem cells. Stem Cell Reports. 2023 04 11; 18(4):829-840.
-
Lamble AJ, Myers RM, Taraseviciute A, John S, Yates B, Steinberg SM, Sheppard J, Kovach AE, Wood B, Borowitz MJ, Stetler-Stevenson M, Yuan CM, Pillai V, Foley T, Chung P, Chen L, Lee DW, Annesley C, DiNofia A, Grupp SA, Verneris MR, Gore L, Laetsch TW, Bhojwani D, Brown PA, Pulsipher MA, Rheingold SR, Gardner RA, Shah NN. Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells. Blood Adv. 2023 02 28; 7(4):575-585.
-
Stefanski HE, Eaton A, Baggott C, Rossoff J, Verneris MR, Prabhu S, Pacenta HL, Phillips CL, Talano JA, Moskop A, Margossian SP, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski MC, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Chinnabhandar V, Goksenin AY, Curran KJ, Mackall CL, Laetsch TW, Schultz LM. Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Adv. 2023 02 28; 7(4):541-548.
-
Niswander LM, Graff ZT, Chien CD, Chukinas JA, Meadows CA, Leach LC, Loftus JP, Kohler ME, Tasian SK, Fry TJ. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against FLT3- mutant acute myeloid leukemia and KMT2A-rearranged acute lymphoblastic leukemia. Haematologica. 2023 02 01; 108(2):457-471.
-
Duarte C, Kamdar M. Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma. Am Soc Clin Oncol Educ Book. 2023 Jan; 43:e390802.
-
Kent A, Pollyea DA. Top advances of the year: Leukemia. Cancer. 2023 04 01; 129(7):981-985.
-
Johnson J, Kim SY, Sam PK, Asokan R, Cari EL, Bales ES, Luu TH, Perez L, Kallen AN, Nel-Themaat L, Polotsky AJ, Post MD, Orlicky DJ, Jordan KR, Bitler BG. Expression and T cell regulatory action of the PD-1 immune checkpoint in the ovary and fallopian tube. Am J Reprod Immunol. 2023 03; 89(3):e13649.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|